They categorized SCLC into four types based on TME association with resistance to platinum-based therapy: SCLC-A with ASCL1 expression, SCLC-I with PD-L1 expression, SCLC-N with NEUROD1 expression, and SCLC-P with POU2F3 expression. This evidence concerns the gene POU2F3 and small cell lung carcinoma.